{"id":"https://openalex.org/W4385694635","doi":"https://doi.org/10.36849/jdd.7471","title":"Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study","display_name":"Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study","publication_year":2023,"publication_date":"2023-07-01","ids":{"openalex":"https://openalex.org/W4385694635","doi":"https://doi.org/10.36849/jdd.7471","pmid":"https://pubmed.ncbi.nlm.nih.gov/37556515"},"language":"en","primary_location":{"id":"doi:10.36849/jdd.7471","doi":"https://doi.org/10.36849/jdd.7471","is_oa":false,"landing_page_url":"https://doi.org/10.36849/jdd.7471","pdf_url":null,"source":{"id":"https://openalex.org/S111565304","display_name":"Journal of Drugs in Dermatology","issn_l":"1545-9616","issn":["1545-9616"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4323285840","host_organization_name":"SanovaWorks","host_organization_lineage":["https://openalex.org/P4323285840"],"host_organization_lineage_names":["SanovaWorks"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Drugs in Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023622070","display_name":"Jayme Heim","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jayme Heim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037648859","display_name":"J Gabriel Vasquez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Gabriel Vasquez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020632357","display_name":"Brad Schenkel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brad Schenkel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5107191377","display_name":"Neal D Bhatia","orcid":"https://orcid.org/0000-0001-7448-7809","observed_orcids":["https://orcid.org/0000-0001-7448-7809"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neal Bhatia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4441,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.55923437,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"22","issue":"8","first_page":"754","last_page":"760"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tildrakizumab","display_name":"tildrakizumab","score":1.0},{"id":"https://openalex.org/keywords/plaque-psoriasis","display_name":"plaque psoriasis","score":0.9020000100135803},{"id":"https://openalex.org/keywords/moderate-to-severe-psoriasis","display_name":"moderate-to-severe psoriasis","score":0.8790000081062317},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.7269999980926514},{"id":"https://openalex.org/keywords/real-world-effectiveness","display_name":"real-world effectiveness","score":0.9240000247955322},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.9629999995231628},{"id":"https://openalex.org/keywords/pasi-90-response","display_name":"PASI 90 response","score":0.9110000133514404},{"id":"https://openalex.org/keywords/body-surface-area-involvement","display_name":"body surface area involvement","score":0.7680000066757202},{"id":"https://openalex.org/keywords/disease-activity","display_name":"disease activity","score":0.6039999723434448},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8330000042915344},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.6050000190734863},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.765999972820282},{"id":"https://openalex.org/keywords/serious-adverse-events","display_name":"serious adverse events","score":0.4269999861717224}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9585711359977722},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.719202995300293},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.6972237229347229},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6350270509719849},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6008106470108032},{"id":"https://openalex.org/C2777501473","wikidata":"https://www.wikidata.org/wiki/Q1796666","display_name":"Body surface area","level":2,"score":0.5505906343460083},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.45830443501472473},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.43945086002349854},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.42209190130233765},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.2849184572696686}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.36849/jdd.7471","doi":"https://doi.org/10.36849/jdd.7471","is_oa":false,"landing_page_url":"https://doi.org/10.36849/jdd.7471","pdf_url":null,"source":{"id":"https://openalex.org/S111565304","display_name":"Journal of Drugs in Dermatology","issn_l":"1545-9616","issn":["1545-9616"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4323285840","host_organization_name":"SanovaWorks","host_organization_lineage":["https://openalex.org/P4323285840"],"host_organization_lineage_names":["SanovaWorks"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Drugs in Dermatology","raw_type":"journal-article"},{"id":"pmid:37556515","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37556515","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of drugs in dermatology : JDD","raw_type":"Clinical Trial, Phase IV"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.6899999976158142}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3176363967","https://openalex.org/W2751316297","https://openalex.org/W1990582125","https://openalex.org/W1989170203","https://openalex.org/W1975896731","https://openalex.org/W2059983379","https://openalex.org/W1485326008","https://openalex.org/W2898213950","https://openalex.org/W1969368658","https://openalex.org/W4385850850"],"abstract_inverted_index":{"BACKGROUND:":[0],"Tildrakizumab":[1],"is":[2],"an":[3],"anti\u2013interleukin-23":[4],"p19":[5],"monoclonal":[6],"antibody":[7],"approved":[8],"for":[9,27],"the":[10],"treatment":[11,184],"of":[12,25,128,211,223],"adults":[13,37],"with":[14,38,193,215],"moderate-to-severe":[15,39],"plaque":[16,40],"psoriasis.":[17],"This":[18],"analysis":[19,222],"evaluated":[20],"real-world":[21],"effectiveness":[22,208],"and":[23,52,64,86,90,157,189,209],"safety":[24,91,196,210],"tildrakizumab":[26,43,183,212],"28":[28,220],"weeks.":[29],"METHODS:":[30],"In":[31],"this":[32],"Phase":[33],"4":[34,226],"study":[35],"(NCT03718299),":[36],"psoriasis":[41],"received":[42],"100":[44],"mg":[45],"subcutaneously":[46],"at":[47,117,124],"week":[48,50,98,125,137,219],"0,":[49],"4,":[51],"every":[53],"12":[54],"weeks":[55],"thereafter.":[56],"Clinical":[57],"improvement":[58],"was":[59],"assessed":[60],"from":[61,70,74,92,114,144,151,161],"Psoriasis":[62],"Area":[63],"Severity":[65],"Index":[66],"(PASI)":[67],"score":[68,110],"change":[69],"baseline;":[71],"disease":[72,191],"activity":[73],"body":[75],"surface":[76],"area":[77],"(BSA)":[78],"percentage":[79],"affected,":[80],"static":[81],"Physician's":[82],"Global":[83],"Assessment":[84],"(sPGA),":[85],"sPGA":[87,150,160],"x":[88,159],"BSA;":[89],"adverse":[93],"events":[94],"(AEs).":[95],"RESULTS:":[96],"At":[97],"28,":[99,138],"52/55":[100],"enrolled":[101],"patients":[102,129,214],"were":[103,171,176],"assessed.":[104],"Mean":[105],"(standard":[106],"deviation":[107],"[SD])":[108],"PASI":[109,131],"decreased":[111,142],"significantly":[112,143,185],"(P<0.001)":[113],"11.6":[115],"(7.1)":[116],"baseline":[118,135],"to":[119,136,147,154,164,179],"1.8":[120],"(3.0;":[121],"82.1%":[122],"improvement)":[123],"28;":[126],"55.8%":[127],"achieved":[130],"90":[132],"response.":[133],"From":[134],"mean":[139],"(SD)":[140],"BSA":[141,158],"14.5%":[145],"(11.5%)":[146],"2.9%":[148],"(6.4%),":[149],"3.2":[152],"(0.6)":[153],"1.2":[155],"(0.9),":[156],"47.0":[162],"(41.5)":[163],"6.8":[165],"(20.3;":[166],"all":[167],"P<0.001).":[168],"Serious":[169],"AEs":[170,175],"infrequent.":[172],"No":[173],"treatment-emergent":[174],"considered":[177],"related":[178],"tildrakizumab.":[180],"Conclusions:":[181],"Real-world":[182,207],"improved":[186],"clinical":[187],"status":[188],"reduced":[190],"activity,":[192],"no":[194],"new":[195],"concerns.":[197],"Heim":[198],"J,":[199,202],"Gabriel":[200],"Vasquez":[201],"Schenkel":[203],"B,":[204],"et":[205],"al.":[206],"in":[213],"moderate-":[216],"to-severe":[217],"psoriasis:":[218],"interim":[221],"a":[224],"phase":[225],"study.":[227],"J":[228],"Drugs":[229],"Dermatol.":[230],"2023;22(8):754-760.":[231],"doi:10.36849/JDD.7471.":[232]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2023-08-10T00:00:00"}